Authors:
Cannon, GW
Caldwell, JR
Holt, P
McLean, B
Seidenberg, B
Bolognese, J
Ehrich, E
Mukhopadhyay, S
Daniels, B
Citation: Gw. Cannon et al., Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium - Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip, ARTH RHEUM, 43(5), 2000, pp. 978-987
Authors:
Day, R
Morrison, B
Luza, A
Castaneda, O
Strusberg, A
Nahir, M
Helgetveit, KB
Kress, B
Daniels, B
Bolognese, J
Krupa, D
Seidenberg, B
Ehrich, E
Citation: R. Day et al., A randomized trial of the efficacy and tolerability of the COX-2 inhibitorrofecoxib vs ibuprofen in patients with osteoarthritis, ARCH IN MED, 160(12), 2000, pp. 1781-1787
Authors:
Ehrich, EW
Schnitzer, TJ
McIlwain, H
Levy, R
Wolfe, F
Weisman, M
Zeng, Q
Morrison, B
Bolognese, J
Seidenberg, B
Gertz, BJ
Citation: Ew. Ehrich et al., Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib, J RHEUMATOL, 26(11), 1999, pp. 2438-2447
Authors:
Morrison, BW
Christensen, S
Yuan, WY
Brown, J
Amlani, S
Seidenberg, B
Citation: Bw. Morrison et al., Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib inpost-dental surgery pain: A randomized, controlled trial, CLIN THER, 21(6), 1999, pp. 943-953
Authors:
Schnitzer, TJ
Truitt, K
Fleischmann, R
Dalgin, P
Block, J
Zeng, Q
Bolognese, J
Seidenberg, B
Ehrich, EW
Citation: Tj. Schnitzer et al., The safety profile, tolerability, and effective dose range of rofecoxib inthe treatment of rheumatoid arthritis, CLIN THER, 21(10), 1999, pp. 1688-1702
Authors:
Morrison, BW
Daniels, SE
Kotey, P
Cantu, N
Seidenberg, B
Citation: Bw. Morrison et al., Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea:A randomized controlled trial, OBSTET GYN, 94(4), 1999, pp. 504-508